AC Immune Receives Second Milestone and New Milestone to Increase the Potential Deal Value of Lilly Morphomerâ„¢ Tau Partnership
- CHF 10 million milestone recognizes development progress
- Updated financial terms add a new CHF 60 million milestone for Phase 2 initiation
- Total potential deal value is now CHF 1.86 billion, up from CHF 1.82 billion
AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company, today announced that it will receive a second milestone payment of CHF 10 million from Eli Lilly and Company on or before March 31, 2020 related to development progress in the small molecule Morphomerâ„¢ Tau aggregation inhibitor program.